Global Blood Therapeutics, Inc.

Global Blood Therapeutics, Inc., a biopharmaceutical company that discovers, develops, and commercializes therapeutics to treat grievous blood-based disorders. The company offers Oxbryta tablets, an oral once-daily therapy for SCD. It also evaluates pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company develops its lead product candidate inclacumab, a human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises and resulting hospital admissions and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. Global Blood Therapeutics, Inc. was incorporated in 2011 and is based in South San Francisco, California with additional locations in Baar, Switzerland; Paris, France; Berlin, Germany; and London, United Kingdom. As of October 5, 2022, Global Blood Therapeutics, Inc. operates as a subsidiary of Pfizer Inc.